Fuji Research Park, R&D Division, Kyowa Hakko Kirin , 1188 , Shimotogari, Nagaizumi-cho, Sunto-gun, Shiuoka , Japan.
J Med Chem. 2018 Nov 21;61(22):10067-10083. doi: 10.1021/acs.jmedchem.8b01200. Epub 2018 Oct 31.
A novel class of PPARγ ligand 1 (EC = 197 nM) with a dibenzoazepin scaffold was identified through high-throughput screening campaign. To avoid the synthetically troublesome chiral center of 1, its conformational analysis using the MacroModel was conducted, focusing on conformational flip of the tricyclic ring and the conformational restriction by the methyl group at the chiral center. On the basis of this analysis, scaffold hopping of dibenzoazepine into dibenzo[ b, e]oxepine by replacing the chiral structures with the corresponding olefinic E/ Z isomers was performed. Consequently, dibenzo[ b, e]oxepine scaffold 9 was developed showing extremely potent PPARγ reporter activity (EC = 2.4 nM, efficacy = 9.5%) as well as differentiation-inducing activity against a gastric cancer cell line MKN-45 that was more potent than any other well-known PPARγ agonists in vitro (94% at 30 nM). The X-ray crystal structure analysis of 9 complexed with PPARγ showed that it had a unique binding mode to PPARγ ligand-binding domain that differed from that of any other PPARγ agonists identified thus far.
通过高通量筛选,鉴定出一种新型的 PPARγ 配体 1(EC=197 nM),其骨架为二苯并氮杂䓬。为避免 1 中复杂的手性中心的合成问题,我们使用 MacroModel 进行了构象分析,重点研究了三环的构象翻转和手性中心甲基的构象限制。在此分析的基础上,通过用相应的烯烃 E/Z 异构体替换手性结构,进行了二苯并氮杂䓬到二苯并[b, e]氧杂䓬的骨架跃迁。结果,开发出了二苯并[b, e]氧杂䓬骨架 9,其对胃癌细胞系 MKN-45 的诱导分化活性非常强(EC=2.4 nM,效价=9.5%),比体外任何其他已知的 PPARγ 激动剂都强(30 nM 时为 94%)。9 与 PPARγ 复合物的 X 射线晶体结构分析表明,它与 PPARγ 配体结合域具有独特的结合模式,与迄今为止鉴定的任何其他 PPARγ 激动剂都不同。